Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...
Spremljeno u:
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
PAGEPress Publications
2025-07-01
|
| Serija: | Dermatology Reports |
| Teme: | |
| Online pristup: | https://www.pagepress.org/journals/dr/article/view/10379 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|